Reviled pharma CEO Martin Shkreli is reportedly about to stop leading one of his companies

Turing Pharmaceuticals, the company founded by Martin Shkreli, is in talks to replace him as CEO, The Wall Street Journal is reporting.

On Thursday morning, Shkreli was arrested in connection with securities-fraud charges, to which he pleaded not guilty.

Citing people familiar with the matter, The Journal reports Shkreli is planning to step down, and it is still undecided whether his replacement will be temporary or permanent.

At Turing, which launched in February 2015, Shkreli acquired the US rights to Daraprim, a 62-year-old anti-parasitic drug, which he then raised the price of by 5,000%. Thursday's arrest was not related to the significant price hike. Shkreli is also the CEO of KaloBios, a public biopharmaceutical company he joined last month.

We've reached out to Turing for comment, and we'll update if we hear back.

NOW WATCH: Researchers found out how many miles a week you need to run to improve your health - and it's surprisingly low

Please enable Javascript to watch this video